SciELO - Scientific Electronic Library Online

 
vol.17 número4Use of secret simulated patient followed by workshop based education to assess and improve inhaler counseling in community pharmacy in Jordan índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Pharmacy Practice (Granada)

versión On-line ISSN 1886-3655versión impresa ISSN 1885-642X

Resumen

GUSTAFSON, Whitney L et al. Real-world study of direct oral anticoagulant dosing patterns in patients with atrial fibrillation. Pharmacy Pract (Granada) [online]. 2019, vol.17, n.4, 1709.  Epub 20-Abr-2020. ISSN 1886-3655.

Background:

Direct oral anticoagulants (DOACs) are preferred for stroke prevention in atrial fibrillation (AF). However, off-label doses have been associated with increased risk of adverse events.

Objective:

The objective of this study was to compare the frequency and outcomes of labeled versus off-label DOAC dosing in patients with AF.

Methods:

This retrospective cohort study included adults diagnosed with nonvalvular AF (NVAF), discharged from University of Utah Health on DOAC therapy between 7/1/2017 and 9/30/2017. The primary outcome was off-label DOAC dosing frequency, defined as dosing inconsistent with manufacturer labeling. Secondary outcomes included variables associated with off-label dosing and a composite of adverse events (major bleeding, thromboembolism, and all-cause mortality) in the 90 days following the index hospital discharge.

Results:

Of 249 included patients, 16.1% were discharged with off-label dosing. Factors associated with off-label dosing included advanced age, lower body mass index, decreased renal function, use of rivaroxaban, and hepatic impairment. The majority of off-label patients (70%) received lower-than-recommended DOAC dosing. Prescriber rationale for off-label prescribing was documented in 25% of patients and included anti-Xa guided dosing, high risk for bleeding or thromboembolism, and prior history of on-therapy adverse events. The rate of adverse events between labeled and off-label DOAC doses was not statistically different (10.0% vs. 6.7%, p=0.299), although this is likely due to small sample size.

Conclusions:

Off-label DOAC prescribing for stroke prevention in NVAF at University of Utah Health was consistent or lower than previously published studies. Off-label dosing most often involved under-dosing of rivaroxaban. Future research should investigate the role of provider rationale and insight in optimizing DOAC therapy outcomes.

Palabras clave : Anticoagulants; Thromboembolism; Atrial Fibrillation; Stroke; Off-Label Use; Drug-Related Side Effects and Adverse Reactions; Patient Outcome Assessment; Retrospective Studies; United States.

        · texto en Inglés     · Inglés ( pdf )